ClinicalTrials.gg
CompletedNCT00965549LanScapeUpdated Jan 8, 2013

Comparison of a Basal Plus One Insulin Regimen With a Biphasic Insulin Regimen in Type 2 Diabetes Patients

A Phase 4 interventional study of INSULIN GLARGINE (HOE901) and Insulin aspart in Diabetes Mellitus, Type 2, sponsored by Sanofi. Completed at 74 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-01-08.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
463
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 — 4 open to participants now, 6 under way, 1 of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 2.

Enrollment
51st of 175
463 · median 253
Started
2009
with 9 others
Phase 4
103 of 176
2 open now
Registered
67th of 176
by date
Lead sponsor
82 of 176
Sanofi

Among the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, this one is the 51st largest by enrollment of the 175 interventional ones that give a count, is one of 10 that started in 2009, is one of 103 in phase 4, and was the 67th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

4 of the 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 176 studies testing Insulin Glargine in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The primary objective is to demonstrate the non-inferiority at six months of a basal plus one insulin regimen (Lantus plus one injection of Apidra) compared with a biphasic insulin regimen (NovoMix 30) at controlling glycosylated haemoglobin (HbA1c) in type 2 diabetes.

The secondary objective are:

  • To compare the proportion of patients in each treatment group reaching HbA1c target (\< 7%) at the end of the treatment period
  • To compare the rates of hypoglycaemia (total, severe, nocturnal)
  • To compare the change in body weight from visit 10 to visit 24
  • To compare the change in diabetes specific quality of life and other patient reported outcomes from visit 10 to visit 24

    • Diabetes Treatment Satisfaction Questionnaire - status and change (DTSQs+c)
    • Audit of Diabetes-Dependent Quality of Life (ADDQoL) questionnaire
    • Insulin Treatment Satisfaction Questionnaire (ITSQ)
    • EuroQoL 5 Dimensions (EQ5D) questionnaire
  • To record the change in the daily dose of insulin from visit 2 to visit 10 and visit 10 to visit 24
03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes mellitus
  • Patients being treated with Lantus once daily, Levemir once or twice daily or NPH insulin once or twice daily as a single insulin for at least three months 10.0% > or = > or = 7.5%
  • \< or = 40 kg/m²
  • If patients are taking oral antidiabetics (OADs), the dose must be stable for at least 1 month
  • Ability and willingness to perform blood glucose monitoring using a blood glucose meter and ability and willingness to use a patient diary
  • Provision of written informed obtained prior to enrollment in the study

Exclusion criteria

Exclusion criteria:

  • Type 1 diabetes mellitus
  • Current or previous treatment with an insulin other than basal insulin (biphasic insulin, short acting insulin, rapid-acting insulin analogue)
  • Treatment with GLP-1 receptor agonists or with DPPIV inhibitors in the 3 months before screening
  • Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before screening or any other unstable (rapidly progressing) retinopathy that may require photocoagulation or surgery during the study (confirmed by an optic fundus exam performed in the 2 years prior to screening)
  • Unable or unwilling to enter either of the treatment arms
  • Women who are pregnant or lactating (women of must have a negative pregnancy test at study entry and a medically approved method)
  • History of to the study drugs or to drugs with a similar chemical structure
  • Treatment with systemic in the 3 months prior to study entry
  • Treatment with any product in the 2 months prior to study entry
  • Current treatment with any non-selective beta-blockers
  • Likelihood of requiring treatment during the study period with drugs not permitted by this clinical protocol
  • cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult
  • Impaired hepatic function as shown by and/or AST greater than three times the at screening
  • Impaired renal function as shown by serum creatinine >135 µmol/l in men and > 110 µmol/l in women at screening
  • History of drug or alcohol abuse
  • Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study
  • Patient unlikely to comply with protocol, e.g. uncooperative attitude, inability to return for follow-up visits, or unlikely to complete the study
  • Patient is the investigator or any sub investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
463 participants (actual)

Study arms

  • Experimental
    Lantus + Apidra basal plus one

    Before randomization (common with arm 2): A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy. 8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued. After randomization: 24 weeks of treatment period: Insulin (Lantus®) + metformin (if applicable) + a single injection of insulin glulisine (Apidra®), the latter administered at the patients largest meal of the day

    Drug: INSULIN GLARGINE (HOE901) · Drug: Insulin Glulisine

  • Active comparator
    NovoMix 30 Biphasic

    Before randomization (common with arm 1): A 1 to 2 weeks of screening period: patients will continue on their current insulin and oral antidiabetic drug (OAD) therapy. 8 weeks of run-in period: patients will switch their treatment for insulin glargine (one daily injection at bedtime) and all OADs (with the exception of metformin) will be discontinued. After randomization: 24 weeks of treatment period: Insulin aspart/ insulin protamine crystallised insulin aspart (NovoMix® 30) + metformin (if applicable)

    Drug: Insulin aspart

Interventions

  • LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)

  • NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)

  • APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)

06

What researchers measure

Primary outcomes

  1. Glycosylated Haemoglobin (HbA1c)

    Time frame: At week 7 and week 32

Secondary outcomes

  1. Weight

    Time frame: At week 8 and week 32

  2. Diabetes specific quality of life measured using ADDQoL (Audit of Diabetes-Dependent Quality of Life questionnaire) and other patient reported outcomes measured using EQ5D (EuroQoL 5 Dimensions questionnaire)

    Time frame: Week 8 and week 32

  3. Hypoglycaemia (total, severe and nocturnal)

    Time frame: At week 0 and week 32

07

Study locations

74 sites
  • Investigational Site Number 204
    Campbelltown, 2560, Australia
  • Investigational Site Number 205
    Campbelltown, 2560, Australia
  • Investigational Site Number 201
    Caulfield, 3162, Australia
  • Investigational Site Number 210
    Daw Park, 5041, Australia
  • Investigational Site Number 214
    Douglas, 4814, Australia
  • Investigational Site Number 203
    Heidelberg, 3081, Australia
  • Investigational Site Number 206
    Herston, 4006, Australia
  • Investigational Site Number 211
    Maroubra, 2035, Australia
  • Investigational Site Number 207
    Meadowbrook, 4131, Australia
  • Investigational Site Number 212
    Melbourne, 3065, Australia
  • Investigational Site Number 209
    Milton, 4064, Australia
  • Investigational Site Number 213
    Nowra, 2541, Australia
  • Investigational Site Number 202
    Parkville, 3050, Australia
  • Investigational Site Number 208
    Southport, 4215, Australia
  • Investigational Site Number 826-109
    Aberdeen, AB251LD, United Kingdom
  • Investigational Site Number 826-118
    Ashton-under-Lyne, OL69RW, United Kingdom
  • Investigational Site Number 826-157
    Ayr, KA66DX, United Kingdom
  • Investigational Site Number 826-149
    Barnsley, S752EP, United Kingdom
  • Investigational Site Number 826-135
    Bath, BA13NG, United Kingdom
  • Investigational Site Number 826-124
    Birmingham, B187QH, United Kingdom
  • Investigational Site Number 826-150
    Birmingham, B95SS, United Kingdom
  • Investigational Site Number 826-106
    Bournemouth, BH77DW, United Kingdom
  • Investigational Site Number 826-136
    Bradford, BD96RJ, United Kingdom
  • Investigational Site Number 826-130
    Bristol, BS105NB, United Kingdom
  • Investigational Site Number 826-114
    Bury St Edmunds, IP332QZ, United Kingdom
  • Investigational Site Number 826-132
    Carmarthen, SA312AF, United Kingdom
  • Investigational Site Number 826-141
    Cheadle, SK86LU, United Kingdom
  • Investigational Site Number 826-112
    Chesterfield, S404TF, United Kingdom
  • Investigational Site Number 826-147
    Chester, CH21UL, United Kingdom
  • Investigational Site Number 826-152
    Chichester, PO196SE, United Kingdom
  • Investigational Site Number 826-159
    Cleveleys, FY53LF, United Kingdom
  • Investigational Site Number 826-113
    Colchester, CO45JL, United Kingdom
  • Investigational Site Number 826-119
    Cornwall, TR13LJ, United Kingdom
  • Investigational Site Number 826-162
    Crawley, RH107DX, United Kingdom
  • Investigational Site Number 826-145
    Dafen, SA14 8QF, United Kingdom
  • Investigational Site Number 826-165
    Dumfries, DG14AP, United Kingdom
  • Investigational Site Number 826-167
    Durham, DH15TW, United Kingdom
  • Investigational Site Number 826-173
    East Kilbride, G758RG, United Kingdom
  • Investigational Site Number 826-105
    Edinburgh, EH164SA, United Kingdom
  • Investigational Site Number 826-115
    Exeter, EX25DW, United Kingdom
  • Investigational Site Number 826-160
    Fleetwood, FY76HD, United Kingdom
  • Investigational Site Number 826-107
    Gateshead, NE96SX, United Kingdom
  • Investigational Site Number 826-127
    Glasgow, G213UW, United Kingdom
  • Investigational Site Number 826-174
    Haddington, EH413PF, United Kingdom
  • Investigational Site Number 826-164
    Hereford, HR12RE, United Kingdom
  • Investigational Site Number 826-126
    High Wycombe, HP112TT, United Kingdom
  • Investigational Site Number 826-102
    Hull, HU32JZ, United Kingdom
  • Investigational Site Number 826-120
    Ipswich, IP45PD, United Kingdom
  • Investigational Site Number 826-163
    Kirkcaldy, KY25AH, United Kingdom
  • Investigational Site Number 826-161
    Lancaster, LA11RP, United Kingdom
  • Investigational Site Number 826-101
    Liverpool, L78XP, United Kingdom
  • Investigational Site Number 826-108
    Liverpool, L97AL, United Kingdom
  • Investigational Site Number 826-122
    Livingston, EH546PP, United Kingdom
  • Investigational Site Number 826-110
    Llantrisant, CF728XR, United Kingdom
  • Investigational Site Number 826-142
    London, N18 1QX, United Kingdom
  • Investigational Site Number 826-123
    London, N195NF, United Kingdom
  • Investigational Site Number 826-166
    London, W91SP, United Kingdom
  • Investigational Site Number 826-137
    Manchester, M85RB, United Kingdom
  • Investigational Site Number 826-156
    Mortimer, RG7 3SQ, United Kingdom
  • Investigational Site Number 826-140
    Newcastle upon Tyne, NE46BE, United Kingdom
  • Investigational Site Number 826-138
    Newport, PO305TG, United Kingdom
  • Investigational Site Number 826-133
    Nottingham, NG72UH, United Kingdom
  • Investigational Site Number 826-121
    Nuneaton, CV107DJ, United Kingdom
  • Investigational Site Number 826-129
    Plymouth, PL53JB, United Kingdom
  • Investigational Site Number 826-116
    Salford, M68HD, United Kingdom
  • Investigational Site Number 826-143
    Scunthorpe, DN15 7BH, United Kingdom
  • Investigational Site Number 826-104
    Sheffield, S57AU, United Kingdom
  • Investigational Site Number 826-103
    St Helens, WA93DA, United Kingdom
  • Investigational Site Number 826-139
    St Leonards on Sea, TN377RD, United Kingdom
  • Investigational Site Number 826-111
    Stevenage, SG14AB, United Kingdom
  • Investigational Site Number 826-131
    Stirling, FK82AU, United Kingdom
  • Investigational Site Number 826-146
    Sunderland, SR47TP, United Kingdom
  • Investigational Site Number 826-128
    Westbury, BA133JD, United Kingdom
  • Investigational Site Number 826-117
    York, YO318HE, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2009
First posted
Aug 25, 2009
Start
Jul 2009
Primary completionActual
Dec 2012
CompletionActual
Dec 2012
Last update
Jan 8, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00965549
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Aug 25, 2009
Start date
Jul 2009
Primary completion
Dec 2012
Completion
Dec 2012
Last update
Jan 8, 2013

Study contacts

Christine van Schalkwyk, MD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Glargine · Insulin glulisine

Start the discussion